Selegiline (Eldepryl®);
This is an irreversible inhibitor of MAO-B, used in patients when there is a deterioration in response to levodopa. Selegiline may have some possible neuroprotective effects; however, it remains to be proven.

Cognitively impaired patients are also poor candidates for this drug.

Selegiline as single agent therapy
Reasonable medication for early-stage patients without disabling symptoms.

Can be used in young patients (<65 years of age).

Selegiline as adjunctive therapy
Can be given in combination with levodopa/benserazide but it will need more clinical studies to establish its efficacy.
Side effects